Veradermics (MANE) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Veradermics (NYSE: MANE):

• 10/22/2026 – Veradermics was given a new $204.00 price target by UBS Group.
• 10/22/2026 – Veradermics had its price target raised by B. Riley Financial from $170.00 to $204.00. They now have a “buy” rating on the stock.
• 10/19/2026 – Veradermics had its price target raised by Needham & Company LLC from $164.00 to $172.00. They now have a “buy” rating on the stock.
• 10/19/2026 – Veradermics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/15/2026 – Veradermics had its “buy” rating reaffirmed by Citigroup.

Veradermics Stock Performance

Shares of NYSE:MANE traded up $3.92 on Tuesday, hitting $133.46. 536,288 shares of the company were exchanged, compared to its average volume of 850,989. The company’s 50 day moving average price is $115.82 and its two-hundred day moving average price is $96.55. Veradermics, Incorporated has a one year low of $32.00 and a one year high of $146.57. The firm has a market capitalization of $5.58 billion and a price-to-earnings ratio of -70.24.

Veradermics (NYSE:MANE) last released its earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, meeting the consensus estimate of ($0.58). Research analysts predict that Veradermics, Incorporated will post -2.87 earnings per share for the current year.

Insider Transactions at Veradermics

In other news, Director John W. Childs sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the sale, the director directly owned 194,117 shares in the company, valued at approximately $20,793,813.04. The trade was a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Reid Alexander Waldman sold 67,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $107.86, for a total value of $7,280,550.00. Following the sale, the chief executive officer owned 170,824 shares in the company, valued at approximately $18,425,076.64. This represents a 28.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 961,000 shares of company stock worth $103,120,220.

Veradermics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for dermatologic conditions. The company’s research and development activities are directed toward treatments for diseases and disorders affecting the skin, hair and nails, with an emphasis on addressing areas where existing treatment options are limited.

Veradermics’ pipeline includes investigational topical therapies designed for conditions such as hair loss and other dermatological disorders.